|
1
|
Hessian PA, Edgeworth J and Hogg N: MRP-8
and MRP-14, two abundant Ca(2+)-binding proteins of
neutrophils and monocytes. J Leukoc Biol. 53:197–204.
1993.PubMed/NCBI
|
|
2
|
Sinha P, Okoro C, Foell D, Freeze HH,
Ostrand-Rosenberg S and Srikrishna G: Proinflammatory S100 proteins
regulate the accumulation of myeloid-derived suppressor cells. J
Immunol. 181:4666–4675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heizmann CW, Fritz G and Schäfer BW: S100
proteins: Structure, functions and pathology. Front Biosci.
7:d1356–d1368. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Srikrishna G: S100A8 and S100A9: New
insights into their roles in malignancy. J Innate Immun. 4:31–40.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan JK, Roth J, Oppenheim JJ, Tracey KJ,
Vogl T, Feldmann M, Horwood N and Nanchahal J: Alarmins: Awaiting a
clinical response. J Clin Invest. 122:2711–2719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vogl T, Eisenblätter M, Völler T, Zenker
S, Hermann S, van Lent P, Faust A, Geyer C, Petersen B, Roebrock K,
et al: Alarmin S100A8/S100A9 as a biomarker for molecular imaging
of local inflammatory activity. Nat Commun. 5:45932014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Chang EW, Wong SC, Ong SM, Chong
DQ and Ling KL: Increased myeloid-derived suppressor cells in
gastric cancer correlate with cancer stage and plasma S100A8/A9
proinflammatory proteins. J Immunol. 190:794–804. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reis-Filho JS and Pusztai L: Gene
expression profiling in breast cancer: Classification,
prognostication, and prediction. Lancet. 378:1812–1823. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holst F, Stahl PR, Ruiz C, Hellwinkel O,
Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke
F, et al: Estrogen receptor alpha (ESR1) gene amplification is
frequent in breast cancer. Nat Genet. 39:655–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sonnenblick A, Fumagalli D, Sotiriou C and
Piccart M: Is the differentiation into molecular subtypes of breast
cancer important for staging, local and systemic therapy, and
follow up? Cancer Treat Rev. 40:1089–1095. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dey N, Smith BR and Leyland-Jones B:
Targeting basal-like breast cancers. Curr Drug Targets.
13:1510–1524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moon A, Yong HY, Song JI, Cukovic D,
Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A and Kim HR:
Global gene expression profiling unveils S100A8/A9 as candidate
markers in H-ras-mediated human breast epithelial cell invasion.
Mol Cancer Res. 6:1544–1553. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin C, Li H, Zhang B, Liu Y, Lu G, Lu S,
Sun L, Qi Y, Li X and Chen W: RAGE-binding S100A8/A9 promotes the
migration and invasion of human breast cancer cells through actin
polymerization and epithelial-mesenchymal transition. Breast Cancer
Res Treat. 142:297–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campbell MJ and Machin D: Medical
Statistics: A Commonsense Approach (3rd). London, UK: Wiley.
1999.
|
|
19
|
Kerdivel G, Flouriot G and Pakdel F:
Modulation of estrogen receptor alpha activity and expression
during breast cancer progression. Vitam Horm. 93:135–160. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyoshi Y, Murase K, Saito M, Imamura M
and Oh K: Mechanisms of estrogen receptor-α upregulation in breast
cancers. Med Mol Morphol. 43:193–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mueller SO, Clark JA, Myers PH and Korach
KS: Mammary gland development in adult mice requires epithelial and
stromal estrogen receptor α. Endocrinology. 143:2357–2365. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang SH, Chen Y and Weigel RJ: GATA-3 as a
marker of hormone response in breast cancer. J Surg Res.
157:290–295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kouros-Mehr H, Slorach EM, Sternlicht MD
and Werb Z: GATA3 maintains the differentiation of the luminal cell
fate in the mammary gland. Cell. 127:1041–1055. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen JQ, Litton J, Xiao L, Zhang HZ,
Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, et al:
Quantitative immunohistochemical analysis and prognostic
significance of TRPS-1, a new GATA transcription factor family
member, in breast cancer. Horm Cancer. 1:21–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kouros-Mehr H, Kim JW, Bechis SK and Werb
Z: GATA3 and the regulation of the mammary luminal cell fate. Curr
Opin Cell Biol. 20:164–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eeckhoute J, Keeton EK, Lupien M, Krum SA,
Carroll JS and Brown M: Positive cross-regulatory loop ties GATA3
to estrogen receptor alpha expression in breast cancer. Cancer Res.
67:6477–6483. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan W, Cao QJ, Arenas RB, Bentley B and
Shao R: GATA3 inhibits breast cancer metastasis through the
reversal of epithelial-mesenchymal transition. J Biol Chem.
285:14042–14051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hobbs JA, May R, Tanousis K, McNeill E,
Mathies M, Gebhardt C, Henderson R, Robinson MJ and Hogg N: Myeloid
cell function in MRP-14 (S100A9) null mice. Mol Cell Biol.
23:2564–2576. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoch RV, Thompson DA, Baker RJ and Weigel
RJ: GATA3 is expressed in association with estrogen receptor in
breast cancer. Int J Cancer. 84:122–128. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gebhardt C, Németh J, Angel P and Hess J:
S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol.
72:1622–1631. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lindau D, Gielen P, Kroesen M, Wesseling P
and Adema GJ: The immunosuppressive tumour network: Myeloid-derived
suppressor cells, regulatory T cells and natural killer T cells.
Immunology. 138:105–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten
DS, Nobel AB, van't Veer LJ and Perou CM: Concordance among
gene-expression- based predictors for breast cancer. N Engl J Med.
355:560–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
